Life Sciences Update - June 2017

Welcome to our Life Science Issue, a monthly update from the Life Sciences team at S&B, containing news about recent and topical developments.

Contact our experts for further advice

View profile for Charlotte TillettCharlotte Tillett, View profile for Gustaf DuhsGustaf Duhs
  1. EU Medical Device and In Vitro Diagnostics Regulations

    The EU's new Medical Device and IVD Regulations took effect in May 2017 and overhaul the regulatory regime to improve product quality, safety and reliability. Maliha Carey, Senior Associate talks to Medtech Insight about the implications and increased burdens for operating businesses in the new environment. 


  2. New UK law to control generic drug prices - implications for pharma

    New UK regulation seeks to clarify and extend the Government’s powers to regulate the cost of medicines and medical supplies and to collect sales and pricing information from pharma. Charlotte Tillett, Partner and Head of Life Sciences and Astrid Arnold, Professional Support Lawyer outline the aims and implications of the new drug pricing legislation, the Health Service Medical Supplies (Costs) Act 2017 in an article in Pharmaphorum.


  3. Location, location, location... European Medicines Agency Brexit guidance published

    With the uncertainty that comes with considering the impact of the “B” word, guidance has recently been published by the European Commission and the European Medicines Agency (EMA) with regard to centrally authorised medicinal products for human... Read more
  4. Developments in the online sale of pharmaceuticals in the EU

    In this article published in Digital Health Legal, Gustaf Duhs, Partner and Head of Competition and Regulatory, sets out a brief summary of the recent case before the CJEU relating to fixed pharmacy prices involving online pharmacy DocMorris and what this ruling means for the online sale of pharmaceuticals in Europe; further, Gustaf considers the latest developments in Germany and more generally in the EU following the CJEU’s decision on the matter.


Search our site